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these three points. First, in the EPaNIC trial, 
early parenteral nutrition failed to improve the 
outcome in the preplanned subgroup of 863 pa-
tients with a very high nutritional risk.3 Second, 
the assumption that more severely ill patients 
would benefit from early enhanced feeding was 
proven wrong; when subgroups were defined 
according to severity of illness on admission, it 
was clear that early parenteral nutrition caused 
the most harm in the most severely ill subgroup, 
whereas the intervention did not alter the out-
come in the least severely ill patients.3 In addi-
tion, the administration of early parenteral nutri-
tion aggravated rather than reduced muscle 
weakness in the sickest patients requiring pro-
longed intensive care.4 Third, a retrospective 
analysis showed that it was the dose of amino 
acids, not the amount of glucose, that ex-
plained the harm evoked by early parenteral 
nutrition, an observation that is completely in 
line with the results from a study of experi-
mentally induced critical illness in rabbits.3,5
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Global Biomedical R&D Expenditures
To the Editor: In their Perspective article, 
Chakma et al. (Jan. 2 issue)1 report estimates for 
global trends in expenditures on health research 
and development (R&D). Their analysis is ques-
tionable. First, expenditure data should be deflat-
ed in the national currency and then compared 
with the use of an appropriate exchange rate for 
one base year. The authors’ approach overesti-
mates growth in countries with relative currency 
appreciation. Second, the standard approach is 
to deflate expenditure data with the use of the 
implicit gross domestic product (GDP) price in-
dex, not the National Institutes of Health R&D 
price index, which flatters countries with high 
inflation. Third, it is better to compare R&D ex-
penditures with the use of GDP purchasing pow-
er parities (PPPs) than with current exchange 
rates, which underestimate the contribution of 
countries in which exchange rates overstate the 
cost of domestic activities and thus of R&D.
When we recalculate the data using 2012 
PPP exchange rates and 2012 GDP prices, China 
(up $8.7 billion between 2007 and 2012) shows 
the largest increase in R&D expenditures, in-
stead of Japan (up $2.8 billion). India (up $1.6 
billion) and South Korea (up $4.3 billion) show 
larger increases than originally estimated; Aus-
tralia’s increase is smaller (up $0.4 billion). The 
decline in the United States is not so marked 
(down $4.0 billion).
Alison J. Young, M.A.
Rue de l’Université 
Paris, France
Robert F. Terry, M.Phil.
TDR, the Special Program for Research and Training  
 in Tropical Diseases 
Geneva, Switzerland 
terryr@who.int
John-Arne Røttingen, M.D., Ph.D.
Norwegian Institute of Public Health 
Oslo, Norway
Roderik F. Viergever, M.D., Ph.D.
Radboud University Medical Center 
Nijmegen, the Netherlands
No potential conflict of interest relevant to this letter was re-
ported.
1. Chakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R. Asia’s 
ascent — global trends in biomedical R&D expenditures. N Engl 
J Med 2014;370:3-6.
DOI: 10.1056/NEJMc1405176
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;25 nejm.org june 19, 20142452
The authors reply: We disagree with the unref-
erenced assertion that the approaches suggested 
by Young et al. are “standard” or “better.” Most 
important, their suggestion to use the implicit 
GDP price index is problematic because it reflects 
economy-wide inflation, not biomedical R&D in-
flation, which diverges significantly from GDP.1,2 
In particular, Young et al. are incorrect to con-
clude that there has been a “not so marked” U.S. 
decline on the basis of economy-wide inflation, 
when U.S. biomedical R&D inflation is known.3,4 
Similarly, their suggestion to use GDP PPP is 
f lawed, because costs of domestic biomedical 
R&D activities and corresponding PPP are un-
known. Decade-long analyses of R&D-specific 
prices show that “at the industry level, use of 
GDP PPP as a proxy for R&D PPP is inappropri-
ate.” 5 Finally, we do agree that currency apprecia-
tion may overstate domestic growth, but on this 
point, our approach and their approach do not 
produce meaningfully dissimilar results. Adjust-
ing historical nominal R&D expenditures at an 
exchange rate from a single time point shows 
similar annual growth rates, except for those in 
Japan and India. Our analysis supporting the 
relative and absolute decline of U.S. spending re-
mains valid.
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Emphysematous Aortitis after Endovascular Graft
To the Editor: Huang and Wu (Jan. 9 issue)1 
report a case of death after endovascular aortic 
repair of a thoracic aortic aneurysm. I was sur-
prised that the authors did not consider the diag-
nosis of aortoesophageal fistula, a rare but well-
known and well-described complication of this 
surgery.2-5 Persistent mechanical pressure from 
the enlarged aneurysm sac causes an erosive 
communication with the adjacent esophagus, 
leading to sac infection and hematemesis. The 
described findings of endoleak (persistent pres-
surization of the aneurysm sac), fever, air in the 
aneurysm adjacent to the esophagus, and death 
due to massive hematemesis strongly suggest a 
diagnosis of aortoesophageal fistula rather 
than poor oral hygiene, as was presumed.
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The Authors Reply: Johnston points out that 
our diagnosis should have been aortoesophageal 
fistula. We agree that aortoesophageal fistula 
may have been the cause of massive hemateme-
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